Concepedia

Prasanna Kumar

PK

16

Publications

668

Citations

12

H-Index

2006

Active since

Affiliations

Daiichi Sankyo (United States)(Current)

Sarah Cannon

The University of Texas MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

Tennessee Oncology

Prasanna Kumar is an author at Daiichi Sankyo (United States) specializing in cancer therapeutics, oncology, and medicine.

ORCID

Top concepts

Publications per year

2006–2023

16

Publications

16

Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody

George A. Dominguez, Thomas Condamine, Sridevi Mony et al. · Clinical Cancer Research · 2016 · 181 citations

Natural History, Predictors and Management of Ureteroenteric Strictures after Robot Assisted Radical Cystectomy

Youssef E. Ahmed, Ahmed A. Hussein, Paul May et al. · The Journal of Urology · 2017 · 83 citations

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

Mrinal M. Gounder, Todd M. Bauer, Gary K. Schwartz et al. · Journal of Clinical Oncology · 2023 · 83 citations · Full text

Adjuvant FOLFOX Chemotherapy and Splenomegaly in Patients with Stages II–III Colorectal Cancer

Revathi Angitapalli, Alan Litwin, Prasanna Kumar et al. · Oncology · 2009 · 46 citations

A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).

Todd M. Bauer, Mrinal M. Gounder, Amy Weise et al. · Journal of Clinical Oncology · 2018 · 43 citations

, , +19

Rows per page

1–5 of 16